Moneycontrol PRO

Anubhav Sahu

Principal Analyst

Moneycontrol Research

Reliance Industries Q4FY21: Strong contribution from digital businesses likely to offset probable weakness in cyclical sectors

BUSINESS

Reliance Industries Q4FY21: Strong contribution from digital businesses likely to offset probable weakness in cyclical sectors

RIL reported a strong sequential improvement for its Oil derivative and retail segments. Petrochemicals exhibited elevated product spreads and in the case of retail, the trend of sequential recovery continued across consumption baskets. Jio continued to report strong numbers despite lower ARPU

Syngene: Heavy investment phase makes it a long-term play

BUSINESS

Syngene: Heavy investment phase makes it a long-term play

Beyond contract research, another trend to watch for Syngene is the pick-up in contract manufacturing business in biologics and APIs

Fed: The US economy has just got vaccinated

TRENDS

Fed: The US economy has just got vaccinated

Even though the next few months of payroll data are expected to be exceptionally good, the Fed will give due credence to the weak macroeconomic situation elsewhere in the world before hinting at a rate hike cycle

A play on likely outperformance of agro-chemical sector in near term

BUSINESS

A play on likely outperformance of agro-chemical sector in near term

Rallis' focus on the contract manufacturing business and filling portfolio gaps are a key watch

What is the endgame for the second wave? How should investors position themselves? Part-2

TRENDS

What is the endgame for the second wave? How should investors position themselves? Part-2

Given improved demand scenario in developed markets and ebbing of health crises elsewhere, India’s export oriented sectors – IT, pharma and chemicals – are expected to outperform in the short to medium run

What is the endgame for the second wave? How should investors position themselves? Part-1

BUSINESS

What is the endgame for the second wave? How should investors position themselves? Part-1

Countries having high coverage of COVID jabs have seen a sharp decline in death rates as the vaccination coverage picked up

Phillips Carbon: Second wave slams brakes on recovery theme

BUSINESS

Phillips Carbon: Second wave slams brakes on recovery theme

The second wave of COVID is likely to have an impact on domestic demand for discretionary players in auto and consumer durables. Phillips Carbon is one such name

Bhansali Engineering Q4: Margins likely to moderate in near term; valuation fair

TRENDS

Bhansali Engineering Q4: Margins likely to moderate in near term; valuation fair

The drivers to watch Bhansali Engineering are a pick-up in the end-market demand and a traction in greenfield capex plan

Deregulation of vaccine rollout: What it means for pharma players

BUSINESS

Deregulation of vaccine rollout: What it means for pharma players

Dr Reddy’s, Gland Pharma, Strides, Cadila, Aurobindo are some of the names that merit a close watch as operating leverage plays out

Solara Active: Aurore deal to act as a booster for CRAMS; accumulate

TRENDS

Solara Active: Aurore deal to act as a booster for CRAMS; accumulate

The Aurore deal should help Solara in ramping up CRAMS portfolio, diversifying the API product basket and also aiding backward integration

What ‘second wave’ means for investors in Indian pharma

TRENDS

What ‘second wave’ means for investors in Indian pharma

Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma

CDMO leader ready to straddle entire pharma value chain

BUSINESS

CDMO leader ready to straddle entire pharma value chain

Except phosgenation and fluorination, Suven Pharma is capable of handling every other chemistry. This adds to the scope for contract engagements in speciality chemicals and clinical development for pharma

Laxmi Organic: Investment horizon should match business transformation time span

BUSINESS

Laxmi Organic: Investment horizon should match business transformation time span

Laxmi Organic is certainly on a transformation mode, and, hence, investors need to be patient enough to witness the change in business mix.

Anupam Rasayan IPO: Has it lost the case with weak listing?

MONEYCONTROL-RESEARCH

Anupam Rasayan IPO: Has it lost the case with weak listing?

Anupam though 1/10th the size of PI Industries, appears to be its good proxy in the field of custom synthesis of agro-chemicals. One of the things which strikes us is the growing export exposure to the lucrative Japanese market.

Bodal Chemicals: On transformation from a dyes major to a diversified play

BUSINESS

Bodal Chemicals: On transformation from a dyes major to a diversified play

Business case for the new capex and acquisition of Bodal Chemicals appears promising, given the import substitution play and higher applications of benzene-based chemicals

Laxmi Organic IPO: A leader in basic chemicals, doubling down on speciality

BUSINESS

Laxmi Organic IPO: A leader in basic chemicals, doubling down on speciality

Re-rating driver for Laxmi Organic depends on success in fluorospeciality, which is likely to be margin-accretive

Anupam Rasayan IPO: A tiny version of PI Industries, diversifying beyond agro-chem

BUSINESS

Anupam Rasayan IPO: A tiny version of PI Industries, diversifying beyond agro-chem

One eye catcher is the growing export exposure for Anupam Rasayan to the lucrative Japanese market

Heranba, a short-term pop or long-term compounder?

BUSINESS

Heranba, a short-term pop or long-term compounder?

Post listing gains, should we look beyond Heranba in agro-chem?

Atul and Amal: When basic chemicals get special

BUSINESS

Atul and Amal: When basic chemicals get special

Basic chemical player Amal warrants investors’ attention just as APIs in the pharma space are getting policy attention

Rain Industries: Time to reap 'end of capex cycle'

BUSINESS

Rain Industries: Time to reap 'end of capex cycle'

Though the Rain stock has firmed up since our last note by 22 per cent, we remain constructive as the valuations are still reasonable

NSE Trading Halt: Outage calls for regulatory action to restore retail investor confidence

BUSINESS

NSE Trading Halt: Outage calls for regulatory action to restore retail investor confidence

Retail equity participants are most vulnerable to the harmful effects of technical failures in the financial market

Aarti Industries: Conviction backed by heavy capex

BUSINESS

Aarti Industries: Conviction backed by heavy capex

Capex projects for Aarti Industries are on track and are backed by a budget of about Rs 1,000-1,200 crore per annum for the next 4-5 years

Heranba IPO: A short-term pop or a long-term compounder?

BUSINESS

Heranba IPO: A short-term pop or a long-term compounder?

Coming to valuations, Heranba appears reasonably priced, given its return ratios and margin profile. The key aspect that differentiates is that China is a major export destination for the company.

What has this Vitamin D API maker to offer beyond Covid opportunity?

BUSINESS

What has this Vitamin D API maker to offer beyond Covid opportunity?

Fermenta Biotech’s near-term growth for the Human Vitamin D3 volume is contingent on commissioning of the Dahej plant in the current quarter

Sections
ISO 27001 - BSI Assurance Mark